山东丰金生物医药

Shandong Fengjin Biological Medicine is a Chinese biopharmaceutical company specializing in the development and commercialization of high-value biologics, including biosimilars and innovative recombinant proteins. Established in 2016 as a subsidiary of the Fengjin Group, the company operates a sophisticated R&D and manufacturing hub in Yantai, Shandong Province. Its therapeutic focus encompasses metabolic disorders, bone health, ophthalmology, and oncology. The company's portfolio features several late-stage candidates, such as biosimilars for denosumab, aflibercept, and semaglutide, alongside its approved teriparatide injection. Fengjin Bio maintains large-scale GMP-compliant production facilities for both mammalian cell culture and microbial fermentation to support its robust pipeline.